sarpogrelate has been researched along with Atherosclerosis in 5 studies
sarpogrelate: structure given in first source
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pravastatin is a lipid-lowering agent that attenuates atherosclerosis." | 7.83 | Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice. ( Heo, TH; Jun, HS; Kwak, MK; Oh, E; Park, KY, 2016) |
| "Indices of insulin resistance (IR) (fasting immunoreactive insulin (IRI) and calculated homeostasis model assessment (HOMA-R)) and adiponectin were measured before and after 2 weeks of sarpogrelate administration (300 mg/day) in 24 patients (19 men, 76+/-9 years) with PAD." | 5.12 | Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. ( Eguchi, M; Hase, M; Hashimoto, A; Kokubu, N; Miura, T; Nagao, K; Nakata, T; Shimamoto, K; Tsuchihashi, K; Tsuzuki, M; Ura, N; Wakabayashi, C; Wakabayashi, T; Yuda, S, 2006) |
| "We have previously shown that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis." | 3.85 | Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis. ( Heo, TH; Park, KY, 2017) |
| "Pravastatin is a lipid-lowering agent that attenuates atherosclerosis." | 3.83 | Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice. ( Heo, TH; Jun, HS; Kwak, MK; Oh, E; Park, KY, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, KY | 2 |
| Heo, TH | 2 |
| Oh, E | 1 |
| Kwak, MK | 1 |
| Jun, HS | 1 |
| Ohata, C | 1 |
| Imamura, T | 1 |
| Xu, YJ | 1 |
| Zhang, M | 1 |
| Ji, L | 1 |
| Elimban, V | 1 |
| Chen, L | 1 |
| Dhalla, NS | 1 |
| Kokubu, N | 1 |
| Tsuchihashi, K | 1 |
| Yuda, S | 1 |
| Hase, M | 1 |
| Eguchi, M | 1 |
| Wakabayashi, T | 1 |
| Hashimoto, A | 1 |
| Nakata, T | 1 |
| Miura, T | 1 |
| Ura, N | 1 |
| Nagao, K | 1 |
| Tsuzuki, M | 1 |
| Wakabayashi, C | 1 |
| Shimamoto, K | 1 |
1 trial available for sarpogrelate and Atherosclerosis
| Article | Year |
|---|---|
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.
Topics: Adiponectin; Aged; Aged, 80 and over; Atherosclerosis; Blood Pressure; Female; Homeostasis; Humans; | 2006 |
4 other studies available for sarpogrelate and Atherosclerosis
| Article | Year |
|---|---|
Critical role of TNF inhibition in combination therapy for elderly mice with atherosclerosis.
Topics: Aging; Animals; Atherosclerosis; Cholesterol, Dietary; Cytokines; Diet, High-Fat; Drug Therapy, Comb | 2017 |
Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.
Topics: Animals; Atherosclerosis; Cell Proliferation; Cytokines; Drug Synergism; Gene Expression Regulation; | 2016 |
Painful purple toes.
Topics: Atherosclerosis; Blue Toe Syndrome; Diagnosis, Differential; Humans; Male; Middle Aged; Myocardial I | 2016 |
Suppression of high lipid diet induced by atherosclerosis sarpogrelate.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Blood Viscosity; Cholesterol, Dietary; Diet, High-Fat; Fo | 2012 |